We are live on ! Find out more
ACM

ADAR1 Capital Management Portfolio holdings

AUM $1.7B
1-Year Est. Return 340.85%
This Fund
S&P 500
This Quarter Est. Return
-5.38%
1 Year Est. Return
+340.85%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$530M
AUM Growth
+$88.9M
Cap. Flow
+$121M
Cap. Flow %
22.77%
Top 10 Hldgs %
58.16%
Holding
331
New
70
Increased
91
Reduced
51
Closed
65

Top Buys

Rank Stock Value
1
CYTK icon
Cytokinetics
CYTK
+$32.3M
2
PTGX icon
Protagonist Therapeutics
PTGX
+$24M
3
BBIO icon
BridgeBio Pharma
BBIO
+$19.5M
4
ROIV icon
Roivant Sciences
ROIV
+$14.9M
5
RPRX icon
Royalty Pharma
RPRX
+$12.8M

Top Sells

Rank Stock Value
1
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$28.1M
2
MACK
Merrimack Pharmaceuticals, Inc.
MACK
+$13.3M
3
EDR
Endeavor Group Holdings, Inc.
EDR
+$3.85M
4
FUSN
Fusion Pharmaceuticals Inc. Common Shares
FUSN
+$3.78M
5
SRPT icon
Sarepta Therapeutics
SRPT
+$3.42M

Sector Composition

Rank Sector Weight
1 Healthcare 80.42%
2 Financials 1.75%
3 Industrials 0.22%
4 Utilities 0.17%
5 Technology 0.15%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ANAB icon
201
CALL
AnaptysBio
ANAB
$1.59B
$37.6K 0.01%
1,500
-500
-25% -$11.6K
ZVSA
202
DELISTED
ZyVersa Therapeutics
ZVSA
$36.1K 0.01%
+9,598
New +$51.5K
PYXS icon
203
Pyxis Oncology
PYXS
$200M
$33.1K 0.01%
10,000
– –
RGNX icon
204
Regenxbio
RGNX
$659M
$31.6K 0.01%
2,700
+200
+8% +$3.11K
BBIO icon
205
PUT
BridgeBio Pharma
BBIO
$15.7B
$30.4K 0.01%
1,200
– –
VTYX
206
DELISTED
Ventyx Biosciences
VTYX
$29.9K 0.01%
12,955
+7,955
+159% +$33.1K
NVO
207
Novo Nordisk
NVO
$196B
$28.5K 0.01%
200
+100
+100% +$13.3K
PRGO icon
208
Perrigo
PRGO
$1.48B
$28.2K 0.01%
1,100
+300
+38% +$8.81K
AMPH icon
209
Amphastar Pharmaceuticals
AMPH
$892M
$28K 0.01%
700
– –
NATL icon
210
NCR Atleos
NATL
$3.47B
$27K 0.01%
1,000
– –
EXAS
211
DELISTED
Exact Sciences
EXAS
$25.4K ﹤0.01%
600
-1,100
-65% -$60.5K
VYX icon
212
NCR Voyix
VYX
$1.22B
$24.7K ﹤0.01%
2,000
– –
AXSM icon
213
Axsome Therapeutics
AXSM
$10.9B
$24.1K ﹤0.01%
+300
New +$22.2K
CELC icon
214
Celcuity
CELC
$4.28B
$22.9K ﹤0.01%
+1,400
New +$23.4K
RAPT
215
DELISTED
RAPT Therapeutics
RAPT
$22.9K ﹤0.01%
+938
New +$43.3K
GHRS icon
216
GH Research
GHRS
$1.93B
$21.6K ﹤0.01%
1,850
-10,733
-85% -$129K
ACAD icon
217
Acadia Pharmaceuticals
ACAD
$4.39B
$21.1K ﹤0.01%
1,300
+800
+160% +$12.9K
LXEO icon
218
Lexeo Therapeutics
LXEO
$330M
$20.9K ﹤0.01%
+1,300
New +$18.9K
SVRA icon
219
CALL
Savara
SVRA
$1.09B
$20.1K ﹤0.01%
+5,000
New +$22.2K
AMPY icon
220
Amplify Energy
AMPY
$166M
$19.9K ﹤0.01%
2,928
-4,153
-59% -$27.3K
AMLX icon
221
CALL
Amylyx Pharmaceuticals
AMLX
$2.24B
$19K ﹤0.01%
10,000
-64,100
-87% -$124K
HIMS icon
222
Hims & Hers Health
HIMS
$7.44B
$19K ﹤0.01%
+940
New +$15.6K
GOSS icon
223
CALL
Gossamer Bio
GOSS
$88.7M
$18K ﹤0.01%
+20,000
New +$15K
PRTC
224
DELISTED
PureTech Health
PRTC
$17.5K ﹤0.01%
+700
New +$19.6K
TMTCR
225
DELISTED
TMT Acquisition Corp Rights
TMTCR
$17K ﹤0.01%
49,900
– –
7 8
9
10 11

Similar funds

RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
AAM
Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return
BCM
BlueCrest Capital Management St Helier, Jersey $1.69B AUM 20.01% 1-Year Est. Return
FDP
Financiere des Professionnels Montreal, Quebec, Canada $1.71B AUM 21.77% 1-Year Est. Return
PP
PDT Partners New York $1.69B AUM 74.01% 1-Year Est. Return
GAM
Goldentree Asset Management New York $1.69B AUM 10.69% 1-Year Est. Return
FACM
Forest Avenue Capital Management Miami, Florida $1.69B AUM 104.84% 1-Year Est. Return
TCBWMS
Texas Capital Bank Wealth Management Services Dallas, Texas $1.68B AUM 21.72% 1-Year Est. Return

ADAR1 Capital Management's Q2 2024 Portfolio in Review

As of Q2 2024, ADAR1 Capital Management held 331 positions worth $530M, up 20% from $441M the previous quarter. Its ten largest holdings account for 58% of the portfolio.

ADAR1 Capital Management deployed $121M of net new capital in Q2 2024, opening 70 new positions and adding to 91 existing holdings. Its largest new stake was Perceptive Capital Solutions: 750,000 shares worth $7.54M.

By sector, the portfolio is most concentrated in Healthcare at 80% of assets, up from 69% a quarter earlier, followed by Financials and Industrials.

On the sell side, the largest reduction was Alnylam Pharmaceuticals, an estimated $28.1M trimmed.

  • ADAR1 Capital Management's largest Q2 2024 buy was Perceptive Capital Solutions: 750,000 shares worth $7.54M.
  • ADAR1 Capital Management added most to Cytokinetics in Q2 2024, an estimated $32.3M increase.
  • ADAR1 Capital Management's biggest Q2 2024 reduction was Alnylam Pharmaceuticals, cutting an estimated $28.1M.
  • ADAR1 Capital Management fully exited Merrimack Pharmaceuticals, Inc. in Q2 2024, selling an estimated $13.3M.
  • ADAR1 Capital Management's ten largest holdings make up 58% of its $530M portfolio in Q2 2024.
  • ADAR1 Capital Management opened 70 new positions and closed 65 in Q2 2024.
  • ADAR1 Capital Management's portfolio value rose 20% quarter-over-quarter to $530M.

Based on ADAR1 Capital Management's 13F filing for Q2 2024, filed 13 Aug 2024.